A Phase 3 interventional study of adalimumab and placebo in Ulcerative Colitis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 65 sites in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2014-09-05.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 10 in phase 3, and was the 5th registered.
1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 274 is above the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 152 across the 18 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
53 studies in Colitis, Ulcerative by AbbVie: 6 open now, 13 under way, 5 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 15th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2009, is one of 19 in phase 3, and was the 9th registered.
AbbVie’s Colitis, Ulcerative studies by the year they started, since 2000.
1 of the studies testing adalimumab in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).
Patients who meet all of the inclusion criteria and none of the exclusion criteria are randomized 1:1:1 to receive subcutaneous injections of adalimumab at either 160/80 mg at Week 0/2 and 40 mg every other week (eow) starting at Week 4 to Week 50, 80/40 mg at Week 0/2 and 40 mg eow starting at Week 4 to Week 50, or placebo eow starting at Week 0 to Week 50 under the double-blind condition. At or after Week 8, participants who have inadequate response during the double-blind period can switch to the rescue arm, where participants from the placebo group initially receive adalimumab 160 mg and 80 mg 2 weeks later and those from the adalimumab group receive adalimumab 40 mg initially and 2 weeks later under double-blind conditions. All participants in the rescue arm then receive 40 mg adalimumab eow until Week 50. Participants who complete the 52-week double-blind period receive open-label adalimumab 40 mg eow starting at Week 52 and continuing until the end of the study. Participants who have an inadequate response or disease flare can dose escalate to 80 mg eow at or after Week 60. Participants who dose escalate to 80 mg eow and continue to have an inadequate response or disease flare are withdrawn from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
Biological: adalimumab · Drug: placebo
Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
Biological: adalimumab
Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
Biological: adalimumab
Also known as: ABT-D2E7 Humira
Percentage of Participants With Clinical Remission at 8 Weeks
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
Time frame: Week 8
Percentage of Participants With Clinical Remission at 52 Weeks
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
Time frame: Week 52
Percentage of Participants With Clinical Remission at 8, 32, and 52 Weeks
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scores from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
Time frame: Weeks 8, 32, and 52
Percentage of Participants With a Clinical Response
A clinical response was defined as a decrease in Mayo score of ≥ 3 points and ≥ 30% from Baseline PLUS a decrease in the Rectal Bleeding Subscore (RBS) ≥ 1 or an absolute RBS of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
Time frame: Baseline and Weeks 8, 32, and 52
Percentage of Participants With Mucosal Healing
Mucosal healing was defined as an endoscopy subscore of ≤ 1 and was assessed using flexible sigmoidoscopy performed at Weeks 8, 32, and 52. The endoscopy subscore ranges from zero to three as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: Weeks 8, 32, and 52
Percentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1)
Rectal bleeding was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The rectal bleeding subscore ranges from zero to three, according to the following scale: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed.
Time frame: Weeks 8, 32, and 52
Percentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1)
The Physician's Global Assessment Subscore acknowledges the three other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from zero to three as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).
Time frame: Weeks 8, 32, and 52
Percentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1)
Stool frequency was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The stool frequency subscore ranges from zero to three, according to the following scale: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal.
Time frame: Weeks 8, 32, and 52
Percentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders
An inflammatory bowel disease questionnaire responder was defined as a participant with at least a 16-point increase from Baseline in total Inflammatory Bowel Disease Questionnaire (IBDQ) score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
Time frame: Baseline and Weeks 8, 32, and 52
Number of Participants With Adverse Events up to Week 8
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.
Time frame: 8 weeks
Number of Participants With Adverse Events up to Week 52
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.
Time frame: 52 weeks
Number of Participants With Adverse Events During the Adalimumab Treatment Period
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.
Time frame: 221 weeks
| Milestone | Double-blind Placebo | Double-blind Adalimumab 80 mg/40 mg | Double-blind Adalimumab 160 mg/80 mg | All Adalimumab |
|---|---|---|---|---|
| Started | 96 | 87 | 91 | 0 |
| Treated | 96 | 87 | 90 | 0 |
| Completed week 8 | 92 | 85 | 86 | 0 |
| Completed | 73 | 58 | 60 | 0 |
| Not completed | 23 | 29 | 31 | 0 |
| Withdrew: Adverse event | 7 | 9 | 13 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 0 | 0 |
| Withdrew: Lack of efficacy | 14 | 17 | 16 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
| Withdrew: Mistreated with rescue study drug | 0 | 0 | 1 | 0 |
| Milestone | Double-blind Placebo | Double-blind Adalimumab 80 mg/40 mg | Double-blind Adalimumab 160 mg/80 mg | All Adalimumab |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 266 |
| Completed | 0 | 0 | 0 | 119 |
| Not completed | 0 | 0 | 0 | 147 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 74 |
| Withdrew: Adverse event | 0 | 0 | 0 | 47 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 20 |
| Withdrew: Other | 0 | 0 | 0 | 6 |
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Percentage of Participants With Clinical Remission at 8 Weeks | 11.5 | 13.8 | 10.0 |
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Percentage of Participants With Clinical Remission at 52 Weeks | 7.3 | 26.4 | 20.0 |
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scores from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Week 8 | 11.5 | 13.8 | 10.0 |
| Week 32 | 8.3 | 17.2 | 17.8 |
| Week 52 | 7.3 | 26.4 | 20.0 |
A clinical response was defined as a decrease in Mayo score of ≥ 3 points and ≥ 30% from Baseline PLUS a decrease in the Rectal Bleeding Subscore (RBS) ≥ 1 or an absolute RBS of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Week 8 | 35.4 | 42.5 | 50.0 |
| Week 32 | 20.8 | 33.3 | 37.8 |
| Week 52 | 17.7 | 29.9 | 31.1 |
Mucosal healing was defined as an endoscopy subscore of ≤ 1 and was assessed using flexible sigmoidoscopy performed at Weeks 8, 32, and 52. The endoscopy subscore ranges from zero to three as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Week 8 | 30.2 | 39.1 | 44.4 |
| Week 32 | 21.9 | 27.6 | 31.1 |
| Week 52 | 15.6 | 28.7 | 28.9 |
Rectal bleeding was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The rectal bleeding subscore ranges from zero to three, according to the following scale: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed.
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Week 8 | 67.7 | 80.5 | 71.1 |
| Week 32 | 28.1 | 40.2 | 43.3 |
| Week 52 | 22.9 | 32.2 | 34.4 |
The Physician's Global Assessment Subscore acknowledges the three other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from zero to three as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Week 8 | 44.8 | 47.1 | 61.1 |
| Week 32 | 28.1 | 36.8 | 37.8 |
| Week 52 | 19.8 | 29.9 | 34.4 |
Stool frequency was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The stool frequency subscore ranges from zero to three, according to the following scale: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal.
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Week 8 | 32.3 | 34.5 | 40.0 |
| Week 32 | 20.8 | 33.3 | 31.1 |
| Week 52 | 13.5 | 28.7 | 28.9 |
An inflammatory bowel disease questionnaire responder was defined as a participant with at least a 16-point increase from Baseline in total Inflammatory Bowel Disease Questionnaire (IBDQ) score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
| percentage of participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Week 8 | 39.6 | 48.3 | 42.2 |
| Week 32 | 21.9 | 33.3 | 28.9 |
| Week 52 | 12.5 | 29.9 | 21.1 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.
| participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Any adverse event | 45 | 49 | 40 |
| Any AE at least possibly drug related | 10 | 14 | 12 |
| Any serious adverse event | 7 | 2 | 4 |
| Any AE leading to discontinuation of study drug | 4 | 0 | 6 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.
| participants | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg |
|---|---|---|---|
| Any adverse event | 67 | 68 | 75 |
| Any AE at least possibly drug related | 17 | 23 | 32 |
| Any serious adverse event | 12 | 14 | 10 |
| Any AE leading to discontinuation of study drug | 5 | 5 | 12 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.
| participants | All Adalimumab |
|---|---|
| Any adverse event | 261 |
| Any AE at least possibly drug related | 142 |
| Any serious adverse event | 90 |
| Any AE leading to discontinuation of study drug | 37 |
Collected over For the 3 randomized treatment arms, adverse events (AEs) were reported from the time of study drug administration up to Week 52 (double-blind period); for All Adalimumab, AEs were reported up to 221 weeks+70 days following discontinuation of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Placebo | — | 13/96 (13.5%) | 51/96 (53.1%) |
| Double-blind Adalimumab 80 mg/40 mg | — | 14/87 (16.1%) | 47/87 (54%) |
| Double-blind Adalimumab 160 mg/80 mg | — | 10/90 (11.1%) | 60/90 (66.7%) |
| All Adalimumab | — | 90/266 (33.8%) | 235/266 (88.3%) |
| Event | Double-blind Placebo | Double-blind Adalimumab 80 mg/40 mg | Double-blind Adalimumab 160 mg/80 mg | All Adalimumab |
|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 8/96 | 5/87 | 5/90 | 38/266 |
| COLONIC POLYPGastrointestinal disorders | 0/96 | 1/87 | 0/90 | 3/266 |
| ADVERSE DRUG REACTIONGeneral disorders | 0/96 | 1/87 | 0/90 | 1/266 |
| BRONCHITISInfections and infestations | 0/96 | 1/87 | 1/90 | 2/266 |
| PNEUMONIA BACTERIALInfections and infestations | 0/96 | 1/87 | 1/90 | 3/266 |
| PYELONEPHRITIS ACUTEInfections and infestations | 0/96 | 1/87 | 0/90 | 2/266 |
| HAND FRACTUREInjury, poisoning and procedural complications | 0/96 | 1/87 | 0/90 | 1/266 |
| WOUNDInjury, poisoning and procedural complications | 0/96 | 1/87 | 0/90 | 1/266 |
| DRUG LEVELInvestigations | 0/96 | 1/87 | 0/90 | 1/266 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/96 | 1/87 | 0/90 | 1/266 |
| Event | Double-blind Placebo | Double-blind Adalimumab 80 mg/40 mg | Double-blind Adalimumab 160 mg/80 mg | All Adalimumab |
|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 21/96 | 19/87 | 30/90 | 162/266 |
| HEADACHENervous system disorders | 6/96 | 3/87 | 7/90 | 42/266 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/96 | 3/87 | 4/90 | 31/266 |
| DENTAL CARIESGastrointestinal disorders | 5/96 | 6/87 | 3/90 | 27/266 |
| UPPER RESPIRATORY TRACT INFLAMMATIONRespiratory, thoracic and mediastinal disorders | 4/96 | 3/87 | 5/90 | 27/266 |
| ECZEMASkin and subcutaneous tissue disorders | 2/96 | 4/87 | 1/90 | 27/266 |
| RASHSkin and subcutaneous tissue disorders | 5/96 | 4/87 | 3/90 | 27/266 |
| NAUSEAGastrointestinal disorders | 4/96 | 2/87 | 5/90 | 26/266 |
| INJECTION SITE REACTIONGeneral disorders | 2/96 | 7/87 | 6/90 | 25/266 |
| IRON DEFICIENCY ANAEMIABlood and lymphatic system disorders | 7/96 | 4/87 | 8/90 | 24/266 |
1 participant in the adalimumab 160 mg/80 mg arm was incorrectly treated with open-label (rescue) study drug at Week 0, and was not included in Baseline Characteristics.
| Age, Continuous(years) | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg | Total |
|---|---|---|---|---|
| Mean | 41.3 ± 13.56 | 44.4 ± 15.04 | 42.5 ± 14.56 | 42.7 ± 14.38 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg | Total |
|---|---|---|---|---|
| Female | 26 | 37 | 29 | 92 |
| Male | 70 | 50 | 61 | 181 |
| Region of Enrollment(participants) | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg | Total |
|---|---|---|---|---|
| Japan | 96 | 87 | 90 | 273 |
| Mayo score(scores on a scale) | Placebo | Adalimumab 80 mg/40 mg | Adalimumab 160 mg/80 mg | Total |
|---|---|---|---|---|
| Mean | 8.5 ± 1.56 | 8.5 ± 1.42 | 8.6 ± 1.44 | 8.5 ± 1.47 |
The record gives a start of Feb 2009, a primary completion of May 2011 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →